### Cisplatin

**Section:** 8. Immunomodulators and antineoplastics  ➤  8.2. Antineoplastics and supportive medicines  ➤  8.2.1. Cytotoxic medicines

- **Indication:** Malignant neoplasms of cervix uteri  
- **ICD11 code:** 2D27
- **ATC codes:** L01XA01
- **INN:** Cisplatin
- **Medicine type:** Chemical agent
- **List type:** Complementary
- **Formulations:** Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL
- **EML status history:**  
  - First added in 1984 (TRS 722)
  - Changed in 2015 (TRS 994)
  - Changed in 2019 (TRS 1021)
  - Changed in 2021
- **Sex:** Female
- **Age:** Adolescents and adults
- **Therapeutic alternatives:** The recommendation is for this specific medicine
- **Patent information:** Patents have expired in most jurisdictions  
  Read more about patents.
- **Tags:** Cancer
- **Wikipedia:** Cisplatin
- **DrugBank:** Cisplatin

## Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the addition of new strength formulations of cisplatin IV injection (10 mg/10 mL and 20 mg/20 mL) to the EML.